Two Sigma Advisers
CYTH

Two Sigma Advisers’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History

Two Sigma Advisers’s Portfolio CYTH Stock Details CYTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,200
Closed -$38K – 2951
2021
Q4 		$38K Sell
10,200
-2,000
-16% -$11.3K ﹤0.01% 2502
2021
Q3 		$82K Buy
+12,200
New +$95.4K ﹤0.01% 2339

Other funds holding CYTH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Advisers's CYTH Position: Q1 2022 in Review

Two Sigma Advisers sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q1 2022, closing a stake of 10,200 shares — an estimated $38K sold.

Two Sigma Advisers first reported a position in CYTH in Q3 2021 and held it in 2 quarters. The position peaked at $82K in Q3 2021. 13 funds tracked by Wall St. Rank hold CYTH as of Q1 2022.

  • Two Sigma Advisers reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Two Sigma Advisers sold 10,200 Cyclo Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $38K.
  • Two Sigma Advisers first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q3 2021 and held it in 2 quarters.
  • Two Sigma Advisers's Cyclo Therapeutics, Inc. Common Stock position peaked at $82K in Q3 2021.
  • 13 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Two Sigma Advisers's 13F filing for Q1 2022, filed 16 May 2022.